Clinical trial · Interventional
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
NCT06711185CI-TRIAL-00083168DAPA-MYOCANCERrecruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dapagliflozin 10 mg | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Dapagliflozin
- description
- Standard chemotherapy treatment + Dapagliflozin 10mg/day.
- interventionNames
- Drug: Dapagliflozin 10 mg
- type
- PLACEBO_COMPARATOR
- label
- Placebo Group
- description
- Standard chemotherapy treatment + Placebo.
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Change in left ventricle ejection fraction
- timeFrame
- 36 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Over 18 years old * Breast cancer * Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin. Exclusion Criteria: * Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves. * Inability to perform CMR due to claustrophobia. * Renal failure with a glomerular filtration rate \< 30 ml/min/1.73 m2. * Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical. * Previous history of significant valvular heart disease. * Previous history of cardiomyopathies.
References
Publications (0)
Data not yet available
No reference posted for this study.